The facts about participating in clinical research and our ongoing studies:
First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.
Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.
For more information, please call: 954-366-0277.
CURRENTLY ENROLLING STUDIES
HOLLYWOOD NEUROLOGY
Lead Study Coordinator: Joel Espinoza
954-981-3850 x302 / jespinoza@infinityclinicalresearch.com
SCARLET ROAD: Memory Loss/Mild Cognitive Impairment
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Two Year Study to Evaluate the Effect of Subcutaneous RO4909832 (Gantenerumab, a monoclonal antibody) on Cognition and Function in Prodromal Alzheimer’s Disease
EPOCH: Alzheimer’s Disease
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931, a Beta-Amyloid Precursor Protein Cleaving Enzyme (BACE) Inhibitor in Subjects with Mild to Moderate Alzheimer’s Disease.
Lead Study Coordinator: Wendy Levy
954-965-4900 x303 / wlevy@infinityclinicalresearch.com
REFLEX: Adult Spasticity
A Phase 3, Randomized, Placebo-Controlled, Parallel-Group, Double Blind, Efficacy and Safety Trial of BOTOX Treatment in Adult Patients with Post-Stroke Lower Limb Spasticity.
VISION: Partial Onset Seizures
A prospective open-label study to the structure and function of the retina in patients with refractory complex partial seizures treated with Vigabatrin (Sabril®).
NORTH SHORE MEDICAL CENTER – FMC CAMPUS
Lead Study Coordinator: Alex Saenz
954-625-3573 / asaenz@infinityclinicalresearch.com
CADENCE-215: Atrial Fibrillation
A Phase 1b, Multi-center, Parallel-group, Double-blind, Placebo-controlled, Randomized, Ascending Dose Trial to Determine the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Infusions of OPC-108459 Administered to Subjects with Paroxysmal or Persistent Atrial Fibrillation
FOREST: Major Depression
To evaluate the efficacy, safety, and tolerability of vilazodone relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD)
EPOCH: Alzheimer’s Disease
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of a Beta-Amyloid Precursor Protein Cleaving Enzyme Inhibitor (BACE) in Subjects with Mild to Moderate Alzheimer’s Disease.
HOLLYWOOD PULMONARY
Lead Study Coordinator: Lucy Vargas
954-981-4491 / lvargas@infinityclinicalresearch.com
SUMMIT: COPD with Cardiovascular Disease
A 1 year, clinical outcomes study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or at risk for cardiovascular disease.
RE2SPOND: COPD Study
A 52 week study to evaluate the efficacy of Roflumilast 500ug on exacerbation rate in subjects with COPD treated with a fixed-dose combination of long-acting beta agonist and inhaled corticosteroid (LABA/ICS). At least 2 documented moderate to severe COPD exacerbations within the last 12 months.
HOLLYWOOD CARDIOLOGY
Lead Study Coordinator: Becky Nembhard
954-965-4900 x173 / rnembhard@infinityclinicalresearch.com
CANTOS: Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A study with a novel new medicine in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction (Heart Attack) Patients
ATMOSPHERE: Chronic Heart Failure
A Multicenter, Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of Both Aliskiren Monotherapy and Aliskiren/Enalapril Combination Therapy Compared to Enalapril Monotherapy, on Morbidity and Mortality in Patients With Chronic Heart Failure (NYHA Class II – IV).
HN REGISTRY: Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia
An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized With Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization.
POMPANO BEACH NEUROLOGY
Lead Study Coordinator: Rebecca Radzivill
954-738-1686 / rradzivill@infinityclinicalresearch.com
PRIME: Relapsing-Remitting and Secondary Progressive MS
A 17-week study to assess the safety and efficacy of an investigational medication in the treatment of central neuropathic pain in patients with MS. For adults between 18-85 years of age.
PREFERMS: Relapsing-Remitting MS
A 1 year study to evaluate Fingolimod (Gilenya) vs. approved 1st line disease modifying therapies in adults newly diagnosed or up to 5 yrs of treatment. For adults 18-65 years of age.
Lead Study Coordinator: Michele Fistel
954-738-1697 / mfistel@infinityclinicalresearch.com
ACCESS: Relapsing-Remitting MS
A 12-month, randomized, rater- and dose-blinded study to compare the efficacy and safety of Fingolimod 0.25 mg and 0.5 mg administered orally with Glatiramer acetate 20 mg administered subcutaneously once daily in patients with relapsing-remitting Multiple Sclerosis.
bioRASI: MS Spasticity
A randomized, double-blind, parallel group study to compare the safety and efficacy of increasing doses of Arbaclofen Extended Release tablets to placebo and Baclofen tablets, for the treatment of spasticity in patients with Multiple Sclerosis
For more information, please call: 954-366-0277.
